Based on CRISPR knockout data, genomic biomarkers and patient data, several target genes were identified as attractive drug targets, including CCND1, INCENP, and EPAS1 represent potentially promising therapeutic targets in ccRCC (Supplementary Data 12). This evidence concerns the gene INCENP and nonpapillary renal cell carcinoma.